IL6 and rheumatoid arthritis: These findings also indicate that the IL-6 signaling pathway may differ in each patient with RA, further supporting the applicability of an assay for assessing pSTAT3-positive CD4+ T cells under IL-6 stimulation as a tool for adjusting the TCZ interval in patients with RA.